An ongoing dialogue on HIV/AIDS, infectious diseases,
November 30th, 2009
WHO HIV Treatment Guidelines Updated
This just in:
WHO is now recommending that ART be initiated at a higher CD4 threshold of 350 cells/mm3 for all HIV-positive patients, including pregnant women, regardless of symptoms.
Which makes eminent sense, of course. Because if starting HIV therapy might prolong survival in developed countries, why shouldn’t it do the same in the developing world?
In fact, when you consider the higher incidence of TB and invasive bacterial infections in such settings, it could easily be argued — and has been argued — that starting early would net greater survival gains in resource-poor settings than it would here.
Plus, there’s the CIPRAHT001 Study, which proves it.
But there’s more — the new WHO guidelines also urge that countries “phase out” the use of stavudine in favor of less-toxic NRTIs, and that women continue breastfeeding so long as they are also on ART.
Good news all around.
Categories: Health Care, HIV, Patient Care, Policy
Tags: AIDS, antiretroviral therapy, antiretrovirals, ART, guidelines, HIV, hiv treatment, Infectious Diseases, WHO
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
2 Responses to “WHO HIV Treatment Guidelines Updated”

Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
Search this Blog
Follow HIV and ID Observations Posts via Email
Archives
Most Popular Posts
Sorry. No data so far.
-
From the Blog — Most Recent Articles
- Farewell to This Blog — and Hello to NEJM Voices March 2, 2026
- Some Ruminations on CROI — Still the Best HIV Meeting February 26, 2026
- Two Things Can Be True: The FDA Process Was Inconsistent, and the mRNA Vaccine Data Were Disappointing February 17, 2026
- Sometimes You Just Need to Get Input from a Real Human Being February 12, 2026
- Mystifying Abbreviations — Infectious Diseases Edition February 4, 2026
FROM NEJM — Recent Infectious Disease Articles- Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts May 14, 2026In a trial, the 3C-like protease inhibitor ensitrelvir was more effective than placebo in preventing Covid-19 in household contacts of patients with SARS-CoV-2 infection.
- Cerebral Syphilitic Gumma May 14, 2026A 50-year-old man presented to the ED with a 1-month history of headache and worsening weakness of the left arm and leg. Brain MRI showed an enhancing lesion with extensive surrounding edema.
- Getting Serious about Tickborne Diseases — Shifting Research Priorities May 13, 2026Research on Lyme disease has emphasized clinical disease and pathogen microbiology rather than the root cause: the infected tick vectors in the environment, which remain uncontrolled.
- Human Infection with Highly Pathogenic Avian Influenza A(H5N5) Virus May 7, 2026Avian influenza can jump species from birds to humans, a fact that arouses concern for serious illness and broader human transmission. In this report, avian influenza A(H5N5) was shown to cause severe human illness.
- Reducing Bacterial Contamination of Blood Bags with a Double Knot May 7, 2026In a study involving 180 blood bags, use of a double-knot closure rather than the usual single knot prevented bacterial contamination. This strategy may reduce the risk of blood-product contamination in resource-limited settings.
- Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts May 14, 2026
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster

Should the guidelines have suggested initiation at < 500 as is expected in the next iteration of US centered guidelines? Although ARVs are limited in many parts of the world should an individual patient be witheld therapy when there is an accumulation of data suggesting 500 (or higher) may be the tipping point? A conundrum in areas where supplies of ARVs are limited perhaps.
CM,
I guess one way of looking at “start at CD4 350” is “start at CD4 > 350.” I realize it’s not exactly the same thing, but since you can’t predict when or if the CD4 will drop, as a pt approaches this threshold (i.e., between 350 and 500), it’s time to get ready to start.
As you know, DHHS guidelines just out as well.
Paul